miR-219-5p inhibits receptor tyrosine kinase pathway by targeting EGFR in glioblastoma.
Glioblastoma is one of the common types of primary brain tumors with a median survival of 12-15 months. The receptor tyrosine kinase (RTK) pathway is known to be deregulated in 88% of the patients with glioblastoma. 45% of GBM patients show amplifications and activating mutations in EGFR gene leadin...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3656853?pdf=render |
id |
doaj-57ff83ca3c5b4eaa806348dd7f0c96b2 |
---|---|
record_format |
Article |
spelling |
doaj-57ff83ca3c5b4eaa806348dd7f0c96b22020-11-25T01:23:40ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0185e6316410.1371/journal.pone.0063164miR-219-5p inhibits receptor tyrosine kinase pathway by targeting EGFR in glioblastoma.Soumya Alige Mahabala RaoArivazhagan ArimappamaganParitosh PandeyVani SantoshAlangar Sathyaranjandas HegdeBangalore Ashwathnarayanara ChandramouliKumaravel SomasundaramGlioblastoma is one of the common types of primary brain tumors with a median survival of 12-15 months. The receptor tyrosine kinase (RTK) pathway is known to be deregulated in 88% of the patients with glioblastoma. 45% of GBM patients show amplifications and activating mutations in EGFR gene leading to the upregulation of the pathway. In the present study, we demonstrate that a brain specific miRNA, miR-219-5p, repressed EGFR by directly binding to its 3'-UTR. The expression of miR-219-5p was downregulated in glioblastoma and the overexpression of miR-219-5p in glioma cell lines inhibited the proliferation, anchorage independent growth and migration. In addition, miR-219-5p inhibited MAPK and PI3K pathways in glioma cell lines in concordance with its ability to target EGFR. The inhibitory effect of miR-219-5p on MAPK and PI3K pathways and glioma cell migration could be rescued by the overexpression of wild type EGFR and vIII mutant of EGFR (both lacking 3'-UTR and thus being insensitive to miR-219-5p) suggesting that the inhibitory effects of miR-219-5p were indeed because of its ability to target EGFR. We also found significant negative correlation between miR-219-5p levels and total as well as phosphorylated forms of EGFR in glioblastoma patient samples. This indicated that the downregulation of miR-219-5p in glioblastoma patients contribute to the increased activity of the RTK pathway by the upregulation of EGFR. Thus, we have identified and characterized miR-219-5p as the RTK regulating novel tumor suppressor miRNA in glioblastoma.http://europepmc.org/articles/PMC3656853?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Soumya Alige Mahabala Rao Arivazhagan Arimappamagan Paritosh Pandey Vani Santosh Alangar Sathyaranjandas Hegde Bangalore Ashwathnarayanara Chandramouli Kumaravel Somasundaram |
spellingShingle |
Soumya Alige Mahabala Rao Arivazhagan Arimappamagan Paritosh Pandey Vani Santosh Alangar Sathyaranjandas Hegde Bangalore Ashwathnarayanara Chandramouli Kumaravel Somasundaram miR-219-5p inhibits receptor tyrosine kinase pathway by targeting EGFR in glioblastoma. PLoS ONE |
author_facet |
Soumya Alige Mahabala Rao Arivazhagan Arimappamagan Paritosh Pandey Vani Santosh Alangar Sathyaranjandas Hegde Bangalore Ashwathnarayanara Chandramouli Kumaravel Somasundaram |
author_sort |
Soumya Alige Mahabala Rao |
title |
miR-219-5p inhibits receptor tyrosine kinase pathway by targeting EGFR in glioblastoma. |
title_short |
miR-219-5p inhibits receptor tyrosine kinase pathway by targeting EGFR in glioblastoma. |
title_full |
miR-219-5p inhibits receptor tyrosine kinase pathway by targeting EGFR in glioblastoma. |
title_fullStr |
miR-219-5p inhibits receptor tyrosine kinase pathway by targeting EGFR in glioblastoma. |
title_full_unstemmed |
miR-219-5p inhibits receptor tyrosine kinase pathway by targeting EGFR in glioblastoma. |
title_sort |
mir-219-5p inhibits receptor tyrosine kinase pathway by targeting egfr in glioblastoma. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2013-01-01 |
description |
Glioblastoma is one of the common types of primary brain tumors with a median survival of 12-15 months. The receptor tyrosine kinase (RTK) pathway is known to be deregulated in 88% of the patients with glioblastoma. 45% of GBM patients show amplifications and activating mutations in EGFR gene leading to the upregulation of the pathway. In the present study, we demonstrate that a brain specific miRNA, miR-219-5p, repressed EGFR by directly binding to its 3'-UTR. The expression of miR-219-5p was downregulated in glioblastoma and the overexpression of miR-219-5p in glioma cell lines inhibited the proliferation, anchorage independent growth and migration. In addition, miR-219-5p inhibited MAPK and PI3K pathways in glioma cell lines in concordance with its ability to target EGFR. The inhibitory effect of miR-219-5p on MAPK and PI3K pathways and glioma cell migration could be rescued by the overexpression of wild type EGFR and vIII mutant of EGFR (both lacking 3'-UTR and thus being insensitive to miR-219-5p) suggesting that the inhibitory effects of miR-219-5p were indeed because of its ability to target EGFR. We also found significant negative correlation between miR-219-5p levels and total as well as phosphorylated forms of EGFR in glioblastoma patient samples. This indicated that the downregulation of miR-219-5p in glioblastoma patients contribute to the increased activity of the RTK pathway by the upregulation of EGFR. Thus, we have identified and characterized miR-219-5p as the RTK regulating novel tumor suppressor miRNA in glioblastoma. |
url |
http://europepmc.org/articles/PMC3656853?pdf=render |
work_keys_str_mv |
AT soumyaaligemahabalarao mir2195pinhibitsreceptortyrosinekinasepathwaybytargetingegfringlioblastoma AT arivazhaganarimappamagan mir2195pinhibitsreceptortyrosinekinasepathwaybytargetingegfringlioblastoma AT paritoshpandey mir2195pinhibitsreceptortyrosinekinasepathwaybytargetingegfringlioblastoma AT vanisantosh mir2195pinhibitsreceptortyrosinekinasepathwaybytargetingegfringlioblastoma AT alangarsathyaranjandashegde mir2195pinhibitsreceptortyrosinekinasepathwaybytargetingegfringlioblastoma AT bangaloreashwathnarayanarachandramouli mir2195pinhibitsreceptortyrosinekinasepathwaybytargetingegfringlioblastoma AT kumaravelsomasundaram mir2195pinhibitsreceptortyrosinekinasepathwaybytargetingegfringlioblastoma |
_version_ |
1725120757702328320 |